#USA #Atlanta #Lymphedema #Celltaxis #LTA4H Inhibitor

Celltaxis' Groundbreaking Publication on Lymphedema Treatment

Celltaxis, a pioneering biotechnology firm focusing on addressing lymphatic diseases, has announced an important publication in Scientific Reports. This peer-reviewed journal, part of the prestigious Nature Portfolio, has detailed significant clinical data regarding the company's innovative therapeutic approach for lymphedema. The study primarily evaluated Celltaxis' foundational drug product—a selective inhibitor of leukotriene A4 hydrolase (LTA4H) intended for use in treating chronic lymphedema.

The published paper, titled "Therapeutic selective leukotriene B4 antagonism for human lymphedema" (DOI 10.1038/s41598-026-67215-4), sheds light on a 12-month open-label, prospective clinical trial assessing the efficacy of the LTA4H inhibitor, acebilustat. Participants included those suffering from Stage II lower-extremity lymphedema who were already on maximized maintenance therapies. The results exhibited enhancements across critical metrics of disease, such as limb volume, skin thickness, tissue structure, and ultimately, quality of life. This outcome not only confirms the symptom relief provided by the treatment but also indicates a potential shift in the disease’s progression.

Eric Springman, Ph.D., who serves as the Co-Founder and Chief Scientific Officer of Celltaxis, remarked on the significance of these findings. He stated, "These published clinical findings represent important independent validation of the therapeutic approach we have been advancing at Celltaxis and provide human evidence supporting a fundamentally different way of treating lymphedema." This statement highlights a key aspect of the treatment: it aims to tackle the underlying inflammatory mechanisms that disrupt lymphatic functionality rather than merely alleviating symptoms.

Scientific evidence has indicated that excessive signaling of leukotriene B4 (LTB4) can hinder healing and regenerative processes within the lymphatic system, thereby aggravating lymphedema. Celltaxis' strategy revolved around selectively suppressing LTA4H, the enzyme responsible for LTB4 production, thereby diminishing inflammatory signaling and aiding in the restoration of lymphatic function. This therapeutic targeting is revolutionary as it shifts the focus from traditional symptom management to addressing the root causes of lymphatic dysfunction.

Lymphedema is characterized as a chronic and often progressive inflammatory condition stemming from lymphatic system damage or dysfunction. The implications of this disorder are profound: patients can experience chronic swelling, tissue remodeling, pain, reduced mobility, and a detrimental decline in quality of life. Current estimates place around 10 million lymphedema patients in the United States alone and approximately 250 million worldwide. Alarmingly, despite its widespread impact, the medical field has yet to standardize any FDA-approved medicinal treatments.

Eileen Heffernan, the Co-Founder and Chief Executive Officer of Celltaxis, expressed the urgency for innovation in lymphatic disease treatment, stating, "Lymphatic diseases represent one of medicine's largest and most overlooked areas of unmet need, yet there has been remarkably little pharmaceutical innovation for the millions of patients living with these chronic disorders." The publication of their findings represents a significant step forward in recognizing and therapeutically addressing the mechanisms behind lymphatic dysfunction.

Dr. Stanley G. Rockson, a prominent figure in lymphatic research at Stanford University, emphasized the importance of these findings for elevating lymphedema treatment. "For far too long, millions of lymphedema patients have felt overlooked... The results of this investigation serve to validate the importance of this molecular pathway in human disease." This underscores a fundamental shift in treatment philosophy, suggesting that managing lymphedema as a dynamic inflammatory condition could lead to pathways that reverse tissue damage rather than merely managing the symptoms.

Key insights from the clinical data included:

• - Reduction in Limb Volume: Patients experienced an average reduction of about one liter in limb volume over the 12-month treatment period, with significant decreases noted within just three months.
• - Decrease in Skin Thickness: Evaluations revealed marked reductions in skin thickness, particularly at the calf and thigh regions.
• - Tissue Architecture Improvements: Advanced imaging techniques indicated favorable changes to tissue structure and extracellular fluid accumulation.
• - Enhanced Quality of Life: Patients reported considerable improvement in quality of life metrics, emphasizing the treatment's holistic benefits.

Celltaxis continues to push the boundaries of biotechnology with the aim of revolutionizing how chronic lymphatic diseases like lymphedema are treated. Through focused research and clinical trials, the company hopes to shift the treatment paradigm for millions of patients currently restricted to lifelong symptom management.